Existing backer Legend Capital contributed to an eight-figure dollar round for the Tsinghua-backed chemistry services provider.

Advancing research from institutions including Harvard, kidney disease-focused Goldfinch Bio now has its sights on clinical trials.

Sinopec Capital and Meinian Onehealth both invested in the biotech research product maker as it prepares for an initial public offering.

Existing backer Gilead Sciences returned for a series B round that boosted the kidney disease therapy developer's total funding to $160m.

Home urinalysis test provider Inui had raised $50m from investors including Fosun and Tencent but is being bought by peer Healthy.io for just $9m.

The autoimmune disease and cancer drug developer plans to float in Hong Kong having recently secured $160m from investors including a Charoen Pokphand-backed fund.

OSF Ventures has exited the medical training game developer two years after providing $2m to take its overall funding to $15m.

The pharmaceutical company co-led a series C round for AAV gene therapy developer Freeline that took its total funding to $275m.

The UC Berkeley-linked cell biology technology provider has raised about $215m in venture funding.

UCLA has been named as the first university partner of an academic collaboration bridge backed by Evotec, Samsara BioCapital and KCK.